$502 Million is the total value of Paradigm Biocapital Advisors LP's 23 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 87.5% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
CCCC | Sell | C4 THERAPEUTICS INC | $552,000 | -95.4% | 73,149 | -85.4% | 0.11% | -96.6% |
FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -212,961 | -100.0% | -1.33% | – |
KYMR | Exit | KYMERA THERAPEUTICS INC | $0 | – | -227,034 | -100.0% | -2.54% | – |
PRTA | Exit | PROTHENA CORP PLC | $0 | – | -267,946 | -100.0% | -2.59% | – |
ZNTL | Exit | ZENTALIS PHARMACEUTICALS INC | $0 | – | -287,577 | -100.0% | -3.51% | – |
HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -136,243 | -100.0% | -3.79% | – |
IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -907,428 | -100.0% | -4.00% | – |
ISEE | Exit | IVERIC BIO INC | $0 | – | -910,416 | -100.0% | -4.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
LEGEND BIOTECH CORP | 8 | Q3 2023 | 10.7% |
MIRATI THERAPEUTICS INC | 8 | Q3 2023 | 10.9% |
VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 6.8% |
IMMUNOCORE HLDGS PLC | 8 | Q3 2023 | 5.9% |
SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
VOR BIOPHARMA INC | 8 | Q3 2023 | 5.0% |
INCYTE CORP | 7 | Q3 2023 | 8.6% |
ARGENX SE | 7 | Q3 2023 | 8.7% |
UNITED THERAPEUTICS CORP DEL | 7 | Q3 2023 | 7.7% |
ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 2.1% |
View Paradigm Biocapital Advisors LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-05-02 |
SC 13G | 2024-04-08 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Paradigm Biocapital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.